CSBR Stock Analysis: Buy, Sell, or Hold?
CSBR - Champions Oncology, Inc.
$5.76
0.40 (7.46%)
▲
5d:
-4.95%
30d:
+0.0%
90d:
-3.84%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Sep 21, 2026
Get Alerted When CSBR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CSBR shows positive signals but monitor for confirmation. Market pricing in 0.1% growth. Moderate conviction.
💡 BUY OPPORTUNITY: CSBR shows positive signals but monitor for confirmation. Market pricing in 0.1% growth. Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CSBR is currently trading at $5.76, which is considered slightly low relative to its 30-day fair value range of $5.61 to $6.21. The stock's valuation (Forward PE: 57.6) is in line with its historical norms (57.5). At these levels, the market is pricing in 0.1% annual earnings growth.
Technical Outlook: Technically, CSBR is showing sideways momentum. Immediate support is located at $5.21, while resistance sits at $6.48. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: CSBR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+108.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CSBR is showing sideways momentum. Immediate support is located at $5.21, while resistance sits at $6.48. The stock is showing strong short-term momentum, up 7.5% recently.
Market Sentiment: CSBR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $12.00 (+108.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.61 -
$6.21
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
65.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.5%)
- BULLISH: Trading 108.3% below Wall St target ($12.00)
- BULLISH: Expecting earnings turnaround to 0.1% growth with 12.0% revenue growth
Trading Range Analysis
30-Day Trading Range
$5.61 -
$6.21
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.22
Resistance Level
$6.48
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
57.60
Wall Street Target
$12.00
(+108.3%)
Revenue Growth (YoY)
12.0%
Earnings Growth (YoY)
-61.1%
Profit Margin
-2.0%
Valuation Premium vs History
+0.1% premium
PE vs Historical
57.6 vs 57.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.1%
(market-implied from PE analysis)
1-Year Target
$5.77
(+0%)
2-Year Target
$5.77
(+0%)
3-Year Target
$5.78
(+0%)
3-Yr Target (if PE normalizes)
(PE: 58→58)
PE COMPRESSION
$5.77
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 57.6, Growth: -16.7%)
$4.20
(+-27%)
Base:
(SPY PE: 20.7, Growth: -16.7%)
$1.51
(-74%)
Bear:
(PE: 17.6, Growth: -16.7%)
$1.28
(-78%)
Share & Embed Analysis
Last updated: August 03, 2026 5:50 PM ET
Data refreshes hourly during market hours. Next update: 6:50 PM
Data refreshes hourly during market hours. Next update: 6:50 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CSBR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 59 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$33 | 58 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 HOLD |
